Abstract 1840P
Background
mCRPC is molecularly heterogenous and PARPi is the only precision medicine for these diseases. PARPi improves outcomes in DNA repair defective (DRD; 20-30%) mCRPC but may also impact other mCRPC molecular subsets not currently encompassed in the FDA approved companion biomarker suite for PARPi. The RNASEH2B gene is located on chromosome 13, flanking RB1, with this locus being commonly lost in mCRPC at treatment resistance, associating with lineage plasticity and genomic instability. RNASEH2B may be co-deleted with RB1, with loss of the former but not the latter sensitising to PARPi. We have hypothesised that RNASEH2B loss in mCRPC is subclonal and that PARPi can clear these RNASEH2B deleted subclones.
Methods
Immunohistochemistry (IHC) for RNASEH2B and RB1, utilising validated assays, was performed on matched (same patient) hormone-sensitive (HSPC) and mCRPC patient biopsies, together with whole-exome sequencing (WES), targeted next-generation sequencing (NGS), and RNA sequencing. Low-pass whole genome sequencing (LP-WGS) was performed on a distinct mCRPC cohort for copy number analysis. RNASEH2B expression was correlated with clinical outcome, DRD and DNA damage signatures.
Results
Subclonal deletions on chromosome 13 encompassing RB1 and RNASEH2B are frequent in HSPC and mCRPC biopsies, although deep deletions are rare, and co-loss of RB1 and RNASEH2B protein is surprisingly uncommon. Heterogeneous and subclonal RNASEH2B protein loss was detected by IHC in mCRPC biopsies, with 54/124 (44%) samples having RNASEH2B loss in 50% cells, although complete RNASEH2B loss is uncommon (8.8%). Interestingly, RNASEH2B loss is not an independent prognostic variable, perhaps related to increasing PARPi and platinum use (50/125 (40%) patients in this study), but did not associate with established DRD or DDR signatures. Studies of the impact of PARPi on RNASEH2B subclone clearance in human mCRPC are ongoing.
Conclusions
RNASEH2B protein is frequently lost in mCRPC subclones, with RB1 loss being less common, and may be of critical importance as this discordant loss is most likely to sensitise to PARPi. This needs further exploration in clinical trials of PARPi.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Royal Marsden Hospital/Institute of Cancer Research.
Funding
Medical Research Council (UK).
Disclosure
C. Lord: Financial Interests, Institutional, Sponsor/Funding, Research funding, consultancy, SAB membership or honoraria payments: AstraZeneca, Merck, KGaA, Artios; Financial Interests, Institutional, Other, consultancy, SAB membership or honoraria payments: Syncona, Sun Pharma, Gerson Lehrman Group, Vertex, Tango, 3rd Rock, Ono Pharma, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, GSK; Financial Interests, Institutional, Stocks/Shares: Tango, Ovibio, Hysplex, Tesselate; Financial Interests, Personal and Institutional, Royalties: DNA repair inhibitors (various organisations) including PARP and ATR inhibitors. A. Sharp: Non-Financial Interests, Principal Investigator, Clinical trial in progress: AstraZeneca, Amgen, Exelixis, Nurix; Non-Financial Interests, Institutional, Product Samples, Access to IMP as a gift for research: AstraZeneca; Non-Financial Interests, Personal, Product Samples, Access to IMP as a gift for research: Cyclacel; Other, Other, Paid consultancy (to research): D.E Research, CHARM Therapeutics; Other, Other, Paid for teaching session: MSD. J.S. de Bono: Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals; Financial Interests, Institutional, Advisory Board: Harpoon; Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, Cellcentric, Daiichi Sankyo, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Vertex Pharmaceuticals, Sanofi Aventis, Sierra Oncology, Taiho, Crescendo Biologics; Non-Financial Interests, Principal Investigator: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Menarini Silicon Biosystems, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals; Non-Financial Interests, Institutional, Product Samples: Daiichi Sankyo, Bayer, Pfizer, Merck Serono, AstraZeneca, Harpoon, Sierra Oncology, Genentech/Roche, Sanofi Aventis, GSK. All other authors have declared no conflicts of interest.
Resources from the same session
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1922P - Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Presenter: Nadia Hindi Muñiz
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15